Genomic medicine France 2025.

The French Plan for Genomic Medicine 2025 was commissioned by Prime Minister Manuel Valls in 2015, and developed by Aviesan (the French National Alliance for Life Sciences and Health) in 2016. It aims to position France as an international leader in personalized and precision medicine, fully integrating genomic medicine into healthcare pathways, and establishing a national genomic medicine industry, that promotes innovation and economic growth. Of the €670M invested in the first five years, around €230M will come from industry. The plan is based on 14 operating measures, linking healthcare, research and industry. Genome sequencing will be performed by 12 ultra-highthroughput services covering the whole country, two of which being launched in 2018. A national data analysis facility (Collecteur analyseur de données, CAD) will interpret and store data, and interface with other national and international databases. A Reference Center for Innovation, Assessment and Transfer (Centre de référence, d’innovation, d’expertise et de transfert, CRefIX), based at academic centers of excellence, is developing the procedures, tools and technologies to be deployrd at the sequencing centers and CAD, and will also be responsible for implementation, commissioning and workforce training. The CrefiX is already operational and has allowed the implementation of the first clinical projects such as pilot cohorts in rare disease, cancer, common disease (diabetes). Moreover, a population cohort will be used in 2016-2018 to test technological, clinical and regulatory barriers. Globally, about 10,000 individuals will be recruited in clinical centers as part of these pilot projects. It is anticipated that France will be capable of sequencing 235,000 genomes per year by 2020, corresponding to 20,000 patients with rare diseases together with their families, and 50,000 high priority patients with metastatic cancer or cancer refractory to treatment. The “French Model” proposed here is a mixed one involving care and research issues, in line with our healthcare system, its link with research, the economic model of diagnostic procedures and the need to set up a process for integrating scientific advances. This Plan also takes into account, in a concrete way, technological progress from sequencing to the storage and analysis of the resultant big data as well as confidential reporting back to doctors and patients. The strong international competition in the field of genomic medicine is explained by the challenges it raises. First and foremost, it is a public health issue. Genomic medicine is revolutionizing the care pathway and therefore how the public health system is organized. A large number of patients with rare diseases or cancer will benefit from routine sequencing of their genomes with more personalized diagnosis and treatment. Great progress has already been made with more common diseases (metabolic, cardiovascular, neurological, etc.) through genome sequencing, above and